The Effectiveness of Nursing Intervention Program on Emotional Distress, Self-Efficacy, and Liver Enzymes Among Hepatitis C Virus Patients Undergoing Antiviral Treatment Therapy (Sovaldi Medication)
American Journal of Nursing Science
Volume 5, Issue 3, June 2016, Pages: 72-84
Received: Mar. 30, 2016; Accepted: Apr. 19, 2016; Published: May 10, 2016
Views 3645      Downloads 122
Authors
Maaly. El. Malky, Psychiatric Nursing Department, Faculty of Nursing, Shebin El-kom, Menoufia University, Egypt
Nahid. El Gahsh, Medical Surgical Nursing Department, Faculty of Nursing, Shebin El-kom, Menoufia University, Egypt
Merfat. M. Atia, Psychiatric Nursing Department, Faculty of Nursing, Shebin El-kom, Menoufia University, Egypt
Article Tools
Follow on us
Abstract
Almost all patients receiving hepatitis C antiviral therapy will experience some treatment-related adverse effects. Emotional distress and fatigue can lead to early treatment discontinuation. Close monitoring is crucial throughout treatment. The nurses can promote adherence by counseling patients on the recognition and management of treatment- related adverse effects. The purpose of the study was to evaluate the effectiveness of nursing intervention program on emotional distress, self-efficacy and liver enzymes among hepatitis C Virus patients undergoing antiviral treatment therapy (Sovaldi medication). Quasi experimental design (one group pre/posttest) was used to achieve the aim of the study. The study was conducted in the Liver Institute at Shebin El kom District, Menoufia Governorate. A purposeful sample of 50 patients with hepatitis C virus patients undergoing antiviral treatment therapy (Sovaldi medication) from the above setting were recruited. Three instrument were used for data collection (1): Structured interview questionnaire to assess demographic and clinical data (2): Hospital anxiety and depression scale to measure emotional distress. (3): Self-efficacy scale to measure patients’ self-efficacy. The result revealed that there were statistical significant improvements of patient’s knowledge, patients’ emotional distress, liver enzymes and self-efficacy post program than preprogram. Conclusion: Nursing intervention program is the key element for management of patients’ emotional distress, self-efficacy and reduction of liver enzymes. Recommendation: psych educational program should be given for all patients with hepatitis C virus undergoing antiviral treatment therapy to improve their knowledge about the drug and promote adherence by counseling patients on the recognition and management of treatment related adverse effect. Encourage them to discuss their problem with health care team and participate in self-help program to decrease emotional distress and increase self-efficacy.
Keywords
Emotional Distress, Self-Efficacy, Liver Enzymes, Nursing Intervention
To cite this article
Maaly. El. Malky, Nahid. El Gahsh, Merfat. M. Atia, The Effectiveness of Nursing Intervention Program on Emotional Distress, Self-Efficacy, and Liver Enzymes Among Hepatitis C Virus Patients Undergoing Antiviral Treatment Therapy (Sovaldi Medication), American Journal of Nursing Science. Vol. 5, No. 3, 2016, pp. 72-84. doi: 10.11648/j.ajns.20160503.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
European Association for Study of Liver. (2014). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology, 60 (2), 392.
[2]
Dhawan, V. K., and Anand, B. S.: Hepatitis C, 2014.
[3]
Ferenci P. Peginterferon and ribavirin in HCV: Improvement of sustained viral response. Best Pract Res Clin Gastroenterol. 2008; 22: 1109–1122. [PubMed]
[4]
Iliades, C. (2014): 8 Ways to Relieve Depression from Hep C, www.everydayhealth.com/.../steps-to-overcoming-depre.
[5]
Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health related quality of life. Hepatology, 45 (3), 806-816.
[6]
Evon, D. M., Golin, C. E., Fried, M. W., & Keefe, F. J. (2013). Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? Journal of -consulting and clinical psychology, 81 (2), 361.
[7]
Foster GR. (2009): Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis.; 16: 605-11.
[8]
American Association, 2014. American Association for the Study of Liver Disease, “AASLD Statement on HCV Guidance,” http://www.aasld.org/practiceguidelines/Pages/AASLDStatementonHCVGuidance.aspx (accessed August 16, 2014).
[9]
Lucinda K. Porter, RN & Alan Franciscus, Editor-in-Chief, HCSP Publications “Gilead Gets U.S. Approval to Sell New Hepatitis C Drug,” The Wall Street Journal, October 10, 2015, http://online.wsj.com/articles/gilead-gets-u-s-approval-to-sell-new-hepatitis-c-drug-1412963083 (accessed October 12, 2015). Approval to Sell New Hepatitis C Drug,” The Wall Street Journal, October 10, 2014, http://online.wsj.com/articles/gilead-gets-u-s-approval-to-sell-new-hepatitis-c-drug-1412963083 (accessed October 12, 2015).
[10]
Ez-Quevedo C, Masnou H, Planas R, Castellvi P, Gimenez D, Morillas RM, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2011; 72 (4): 522–528. [PubMed]
[11]
Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008; 57 (4): 531–536. [PubMed]
[12]
Gilead, A. (2013): Gilead's Sciences, Inc. Sovaldi is a registered trademark of Gilead's Sciences, Inc. available at www.gilead.com
[13]
Jake Liang and Marc G. Ghany, “Editorial: Therapy of Hepatitis C—Back to the Future,” New England Journal of Medicine (May 2014): 1–5, http://globalhealth.med.ucla.edu/programs/therapyofhepc.pdf.
[14]
Avik Roy, “The Sovaldi Tax: Gilead Can’t Justify the Price It’s Asking for Hepatitis C Therapy,” Forbes, June 17, 2014, http://www.forbes.com/sites/theapothecary/2014/06/17/the-sovaldi-tax-gilead-cant-justify-the-price-its-asking-americans-to-pay (accessed December 12, 2014).
[15]
Jonathan D. Rockoff, “Gilead Gets U.S. Approval to Sell New Hepatitis C Drug,” The Wall Street Journal, October 10, 2015, http://online.wsj.com/articles/gilead-gets-u-s-approval-to-sell-new-hepatitis-c-drug-1412963083 (accessed October 12, 2015).
[16]
Gilead, 2015 “Gilead Gets U.S. Approval to Sell New Hepatitis C Drug,” The Wall Street Journal, October 10, 2015, http://online.wsj.com/articles/gilead-gets-u-s-approval-to-sell-new- hepatitis-c-drug-1412963083 (accessed October 12, 2015).
[17]
Tawfik EH. (2011): Impact of an educational program on Health Related Quality of Life among virus hepatitis c patients. Alexandria University. High Institute of Public Health.
[18]
Stephen Miller, “State Governments May Spend $55 Billion on Hepatitis C Medications,” Express Scripts, posted July 17, 2014, http://lab.express-scripts.com/insights/specialty medications/state-governments-may-spend-$55-billion- on-hepatitis-c-medications (accessed January 25, 2015).
[19]
Waldman R., (2014) Gilead's HCV drug Sofosbuvir approved by the FDAbut accessible for how many? Doctors of the world; 6 (4); 27-4Retrived on 22 February.
[20]
Sgorbini, M., O’Brien, L., & Jackson, D. (2009). Living with hepatitis C and treatment: the personal experiences of patients. Journal of clinical nursing, 18 (16), 2282-2291.
[21]
Hong, B. A., North, C. S., Pollio, D. E., Abbacchi, A., Debold, C., Adewuyi, S. A., & Lisker-Melman, M. (2011). The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion. Journal of clinical psychology in medical settings, 18 (1), 99-107.
[22]
Zigmond, AS; Snaith, RP (1983): "The hospital anxiety and depression scale". Acta Psychiatrica Scandinavica 67 (6): 361–370. doi:10.1111/j.1600-0447.1983.tb09716.x. PMID 6880820.
[23]
Lorig K, Stewart A, Ritter P, González V, Laurent D, & Lynch J, Outcome Measures for Health Education and other Health Care Interventions. Thousand Oaks CA: Sage Publications, 1996, pp. 24-25, 41-45.
[24]
Jacobson E. Progressive relaxation. Chicago: University of Chicago Press. 1938.
[25]
Silberbogen, A. K., Ulloa, E. W., Janke, E. A., & Mori, D. L. (2009). Psychosocial issues and mental health treatment recommendations for patients with hepatitis C. Psychosomatics, 50 (2), 114-122.
[26]
Ford, J. A., & Cheong-Lee, C. (2007). The role of the hepatology nurse in the difficult-to- treat hepatitis C population. Canadian Journal of Gastroenterology, 21 (6), 353.
[27]
Mohsen, M. M., Fareed, M. E., El-Sheikh, A. A., & Abbas, S. M. (2011). Effect of nursing management protocol on selected side effects of interferon and ribavirin among hepatitis C patients. Journal of American science, 7 (6), 54-63.
[28]
Foster GR et al (2015). Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. EASL 50th International Liver Congress, Vienna, abstract L05, 2015.
[29]
El-Maksoud, M. M. A., El-Mohsen, A. S. A., Talhat, T., & Abdalla, N. Nursing Intervention for Changing the Lifestyle of Chronic Hepatitis C. Volume 4, Issue 4 Ver. IV (Jul. - Aug. 2015), PP 75-83 www.iosrjournals.org
[30]
Hauschild, A. Gogas, H. Tarhini, A. Middleton, M, R. Testori, A. Brigitte, D. Kirkwood, J, M. (2008): Practical Guidelines for theManagement of Interferon-a-2b Side Effects in Patients Receiving Adjuvant Treatment for Melanoma, onlinelibrary.wiley.com/doi/10.1002/cncr.23251/pdf.
[31]
Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Peters, M. E., & Bleijenberg, G. (2008). Severe fatigue and related factors in cancer patients before the initiation of treatment. British Journal of Cancer, 99, 1408–1414.
[32]
Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43 (4): 661–672.
[33]
Morgan, L. A.,: Nursing Responsibilities in Patients with Hepatitis C. 2012. http://www.ehow.com/list_6137912_nursing-responsibilities-patients-hepatitis- c.html#ixzz2Fugd89DK
[34]
Fareed M. (2004). Dietary management in chronic renal failure patients and its effects on nutritional states, renal function tests and serum electrolytes. Unpublished Doctoral degree, Faculty of Nursing; Menoufyia University.
[35]
National Hepatitis C Program. (2007). Interferon and Ribavirin treatment side effects. United States Development and Veterans Affairs. 1 (1): 1-12.
[36]
Ramsey, S. E., Engler, P. A., Stein, M. D., Brown, R. A., Cioe, P., Kahler, C. W.,... & Solomon, D. A. (2011). Effect of CBT on depressive symptoms in methadone maintenance patients undergoing treatment for hepatitis C. Journal of addiction research & therapy, 2 (2), 2.
[37]
Katon, W. J., Lin, E. H., Von Korff, M., Ciechanowski, P., Ludman, E. J., Young, B.,... & McCulloch, D. (2010). Collaborative care for patients with depression and chronic illnesses. New England Journal of Medicine, 363 (27), 2611-2620.
[38]
Johnson, M. O., Chesney, M. A., Goldstein, R. B., Remien, R. H., Catz, S., Gore-Felton, C.,... & Morin, S. F. (2006). Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model. AIDS Patient Care & STDs, 20 (4), 258-268.
[39]
Rueda, S., Park-Wyllie, L. Y., Bayoumi, A. M., Tynan, A. M., Antoniou, T. A., Rourke, S. B., & Glazier, R. H. (2006). Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev, 3 (3).
[40]
Larrey, D., Salse, A., Ribard, D., Boutet, O., Hyrailles–Blanc, V., Niang, B.,... & Karlova, N. (2011). Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin. Clinical Gastroenterology and Hepatology, 9 (9), 781-785.
[41]
Heneedy W. (2009) Study of the effect of nursing intervention on physical responses and compliance among patients with liver cirrhosis at National Liver Institute and Menoufyia university hospital. Unpublished Doctoral Thesis, Faculty of Nursing; Menoufyia University.
[42]
Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T and Baralle F. (2006). Preliminary report of Interferon Alfa 2b in combination with Ribivirin for 48 weeks for treatment of Iranian patients with chronic hepatitis C: A quasi-experimental study. Shiraz E-Medical Journal, 7 (1): 1-11.
[43]
Rusu, E., Jinga, M., Enache, G., Rusu, F., and et al.: Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C – a randomized trial. Nutrition Journal; 2013, 12: 119. http://www.nutritionj.com/content/12/1/119
[44]
Patrick, C, D. (2014): Liver blood tests, Available at www. medicinenet.com › home › liver blood tests index.
[45]
Constantin, C, V. Teodor, C, S. Maria, L, S. Gabriel, A, I. Sima, F. (2009): Psychosocial stress and liver disease status, World J Gastroenterol, v, 15 (24), Available at www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC).
[46]
Yuan, F, K. Albert, C, Y. Jen, S, T. Zhou, Y. Ming, L, X. (2013): Physiologic and laboratory correlates of depression, anxiety, and poor sleep in liver cirrhosis, BMC Gastroenterol, V, 13 (18), Available at www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC).
[47]
Tahmassian, K., & Jalali Moghadam, N. (2011). Relationship between self-efficacy and symptoms of anxiety, depression, worry and social avoidance in a normal sample of students. Iranian journal of psychiatry and behavioral sciences, 5 (2), 91-98.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186